Compound: Brivaracetam
SMILES: O=C1N([C@H](C(=O)N)CC)C[C@@H](C1)CCC
InChIKey: MSYKRHVOOPPJKU-BDAKNGLRSA-N
Synonyms: Brivaracetam, 357336-20-0, Briviact, UCB 34714, UCB-34714, UCB34714, (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide, U863JGG2IA, 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-, CHEBI:133013, DTXSID00905081, (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, brivaracetamum, RefChem:57048, N03AX23, DTXCID601334183, (2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE, 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide, MFCD25976668, (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, Rikelta, Brivaracetam [USAN:INN], UNII-U863JGG2IA, Brivaracetam?, (2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide, compound 83alpha, (R)-Atomoxetine, Briviact (TN), 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; Brivaracetam; Briviact; UCB 34714, BRIVARACETAM [MI], BRIVARACETAM [INN], BRIVARACETAM [JAN], BRIVARACETAM [USAN], Brivaracetam [EP monograph], BRIVARACETAM [MART.], orb363926, BRIVARACETAM [WHO-DD], SCHEMBL122081, Brivaracetam (JAN/USAN/INN), CHEMBL607400, GTPL9041, AE5 - Anti-epileptic drugs 5, (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butanamide, DEA NO. 2710, MSYKRHVOOPPJKU-BDAKNGLRSA-N, BRIVARACETAM [ORANGE BOOK], GLXC-27574, EX-A2748, BDBM50422531, AKOS027324306, CCG-266666, CS-3418, DB05541, NCGC00390779-02, AC-29289, AS-35277, BB161996, HY-14449, NS00068020, D08879, Q408099, BRD-K00634421-001-01-0, (2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide, (2S)-2-[(4R)-2-Oxo-4-propyl-1-pyrrolidinyl]butanamide, (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide, 1-Pyrrolidineacetamide alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-
Theoretical properties:
molecular_formula: C11H20N2O2
molecular_weight: 212.29 g/mol
exact_mass: 212.152477885 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 5
heavy_atom_count: 15
topological_polar_surface_area: 63.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Brivaracetam is a non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. It has a role as an anticonvulsant. It is a gamma-lactam and a non-proteinogenic amino acid derivative. It is functionally related to a L-alpha-aminobutyric acid.
chebi: A non-proteinogenic amino acid derivative that is butanamide in which the <em> pro-<i>S</i></em> hydrogen at position 2 is replaced by a (4<i>R</i>)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.
chembl: BRIVARACETAM is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.